Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Medigen Vaccine BiologicsROCO:6547 -1.69%67 Quick Ratio is 18.16 as of Jun. 2026, which is 138% above its 10-year median of 7.64. GuruFocus rates ROCO:6547 with a GF Score™ of 67/100 and a GF Value™ of NT$53.81 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 1,410 Biotechnology companies, Medigen Vaccine Biologics ranks better than 91.35% on this metric.
Medigen Vaccine Biologics (ROCO:6547) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Medigen Vaccine Biologics Quick Ratio Related Terms
Medigen Vaccine Biologics Quick Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6547 vs VRTX, REGN, MRNA: Quick Ratio Comparison
For the Biotechnology subindustry, Medigen Vaccine Biologics's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medigen Vaccine Biologics Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Medigen Vaccine Biologics's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Medigen Vaccine Biologics's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Medigen Vaccine Biologics's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medigen Vaccine Biologics (ROCO:6547) has a Quick Ratio of 18.16 as of Jun. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Medigen Vaccine Biologics and its competitors. This is 138% above median its historical median of 7.64. Over the past decade, Medigen Vaccine Biologics' Quick Ratio has ranged from 1.73 to 23.62. According to the industry distribution chart, Medigen Vaccine Biologics ranks #122 out of 1410 companies in the Biotechnology industry, placing it in the top 8.7%.
Is Medigen Vaccine Biologics' Quick Ratio too high?
Medigen Vaccine Biologics' current Quick Ratio of 18.16 is 138% above median its 10-year median of 7.64. Over the past 10 years, this metric has ranged from a low of 1.73 to a high of 23.62. The Biotechnology industry median Quick Ratio is 3.68. Medigen Vaccine Biologics' value of 18.16 is 394.1% above this industry median. Based on the distribution chart, Medigen Vaccine Biologics ranks #122 out of 1410 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Medigen Vaccine Biologics has a GF Score™ of 67/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Medigen Vaccine Biologics' Quick Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Medigen Vaccine Biologics ranks #122 out of 1410 companies for Quick Ratio. This places Medigen Vaccine Biologics in the top 9% of its industry — outperforming the majority of peers. The industry median Quick Ratio is 3.68. Medigen Vaccine Biologics' value of 18.16 is 394.1% above this benchmark. Historically, Medigen Vaccine Biologics' own Quick Ratio has ranged from 1.73 to 23.62 over the past decade. While the company's 10-year median is 7.64 vs. the industry median of 3.68, Medigen Vaccine Biologics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.68, based on 1,410 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medigen Vaccine Biologics's current Quick Ratio of 18.16 is 394.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Medigen Vaccine Biologics and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medigen Vaccine Biologics's current Quick Ratio is 18.16, which is 138% above median its own 10-year median of 7.64. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medigen Vaccine Biologics stock overvalued right now?
Based on GuruFocus' analysis, Medigen Vaccine Biologics (ROCO:6547) is currently considered Modestly Overvalued. The stock's GF Value™ is NT$53.81, compared to a current price of NT$63.90 — trading 18.8% above its estimated fair value. The current Quick Ratio is 18.16, which is 138% above median its 10-year median of 7.64 and 394.1% above the Biotechnology industry median of 3.68. Medigen Vaccine Biologics' overall GF Score™ is 67/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Medigen Vaccine Biologics (ROCO:6547), the current Quick Ratio is 18.16 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medigen Vaccine Biologics (ROCO:6547) Overvalued in 2026?
Based on GuruFocus' analysis, Medigen Vaccine Biologics stock appears to be overvalued.
The current stock price of NT$63.90 is trading 18.8% above its estimated GF Value™ of NT$53.81.
GuruFocus considers Medigen Vaccine Biologics to be Modestly Overvalued.
Key valuation signals for ROCO:6547:
Quick Ratio: 18.16 (138% above median its 10-year median of 7.64)
GF Value™: NT$53.81 vs. price of NT$63.90 (18.8% above fair value)
Industry Position: 394.1% above the Biotechnology median (#122 of 1410)
No single metric tells the full story. See the ROCO:6547 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medigen Vaccine Biologics Corp is engaged in the research, development and wholesale of vaccine and biopharmaceutical, medical devices wholesale and retail, etc. Its products include dengue vaccine, anti-RSV biosimilars, COVID-19 vaccines, enterovirus A71 vaccine, and influenza vaccine QIZ. It operates business only in a single industry in Taiwan.
67GF Score
Get the complete analysis for ROCO:6547
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6547 has been successfully added to your 
